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Abstract
A response to the letter regarding The BRAIN TRIAL: a randomized, placebo controlled trial of a
Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Mr Vincent
Simmon President and CEO of Xytis Inc.
Letter
We were disappointed to read that [1] Mr Simmon has
repeated the claims and allegations about Serious Adverse
Events that were withdrawn in full by Xytis during the
legal proceedings in the High Court of Justice. We do not
think it would be appropriate to consider these claims and
allegations here, instead we direct readers to the public
documentation surrounding this litigation that are availa-
ble on the trial website [2].
Mr Simmon correctly points out that the trial manuscript
[3] quotes the primary analysis as stated in the protocol
rather than the primary objective.
We state clearly in the manuscript that both intention to
treat (ITT) and per protocol analyses (PP) were con-
ducted. For the primary end point both analyses are pre-
sented but for remainder, only ITT analysis was presented
since there was no material difference between them.
Although Xytis sought termination of the trial contract
with LSHTM in November 2007, no request was made for
the termination of the trial. Indeed, in December 2007,
Xytis sought and obtained a High Court injunction pre-
venting the Trial Steering Committee or Data Monitoring
Committee from making any recommendations for the
termination of the trial.
Mr Simmon admits to having accessed the un-blinded
data from the BRAIN trial. This was not permitted accord-
ing to the trial protocol which states that "None of the per-
sons directly involved in the conduct of the trial will have
access to the treatment codes." Neither Ian Roberts nor
Haleema Shakur had access to the treatment codes. As
members of the Trial Steering Committee Ian Roberts and
Haleema Shakur were shown selected tables of un-
blinded data by the Data Monitoring Committee in order
to judge whether the trial should continue. This was per-
mitted by the trial protocol. However, the allegation that
they were un-blinded to the data while queries were on-
going and prior to the final data analysis is false.
The HIREOS Scale is a modified version of the Oxford
Handicap Scale. Its use in the BRAIN trial was specified in
the agreed trial protocol. A paper reporting the predictive
validity of the scale has been published [4].
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We will not comment on the additional data analyses pre-
sented by Mr Simmon since these analyses were not spec-
ified in the Statistical Analysis Plan and are not relevant to
the trial report.
After a long and expensive legal battle we are pleased that
Trials has published the results of the BRAIN trial thus
allowing us to meet our ethical obligations to the trial par-
ticipants that the data are made publicly available.
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